Mechanism of action of bile acid-farnesoid X receptor-intestinal microecological axis in the development of liver failure and liver regeneration

Yanyan CHEN; Yanmei LAN; Minggang WANG; Dewen. MAO

doi:10.3969/j.issn.1001-5256.2021.02.049

Volume 37 Issue 2

Mar. 2021

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(2): 480-484

PDF( 1878 KB)

Mechanism of action of bile acid-farnesoid X receptor-intestinal microecological axis in the development of liver failure and liver regeneration

DOI: 10.3969/j.issn.1001-5256.2021.02.049

1.
Department of Basic Medicine, Hunan Traditional Chinese Medical College, Zhuzhou, Hunan 412000, China
2a.
Department of Scientific Research, Nanning 530023, China
2b.
Department of Hepatology, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning 530023, China

Received Date: 2020-07-16
Accepted Date: 2020-08-17
Published Date: 2021-02-20

Abstract

Abstract

Liver failure is a common critical medical disease, and extensive liver cell necrosis within a short period of time exceeds the regeneration capacity of liver cells and thus results in an extremely high fatality rate. Promotion of effective liver regeneration is the key to antagonizing liver failure. Recent studies have shown that bile acid, farnesoid X receptor (FXR), and intestinal microecology play an important role in liver failure and liver regeneration. This article reviews the association between bile acid, FXR, and intestinal microecology and their role in liver failure and liver regeneration, so as to provide new ideas for the treatment of liver failure in clinical practice.
- Liver Failure,
- Liver Regeneration,
- Bile Acid,
- Farnesol Receptor R,
- Gastrointestinal Microbiome

FullText(HTML)

References(59)

References

[1]	Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure (2018)[J]. J Clin Hepatol, 2019, 35(1): 38-44. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2019.01.007 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007
[2]	AMIN AA, AGARWAL B, JALAN R. Acute liver failure: Updates in pathogenesis and management[J]. Medicine (Abingdon), 2019, 47(12): 1-5.
[3]	MA Z, WU Y. Current status of liver failure treatment[J]. J Clin Hepatol, 2016, 32(9): 1668-1672. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2016.09.007 马臻, 乌云. 肝衰竭的治疗现状[J]. 临床肝胆病杂志, 2016, 32(9): 1668-1672. DOI: 10.3969/j.issn.1001-5256.2016.09.007
[4]	WANG XJ, ZHANG XP, NING Q. Immune-mediated liver failure[J]. J Clin Hepatol, 2014, 30(10): 984-991. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2014.10.004 王晓晶, 张小平, 宁琴. 肝衰竭的免疫发病机制[J]. 临床肝胆病杂志, 2014, 30(10): 984-991. DOI: 10.3969/j.issn.1001-5256.2014.10.004
[5]	MA H, PATTI ME. Bile acids, obesity, and the metabolic syndrome[J]. Best Pract Res Clin Gastroenterol, 2014, 28(4): 573-583. DOI: 10.1016/j.bpg.2014.07.004
[6]	MYANT NB, MITROPOULOS KA. Cholesterol 7 alpha-hydroxylase[J]. J Lipid Res, 1977, 18(2): 135-153. DOI: 10.1016/S0022-2275(20)41693-1
[7]	LI T, CHIANG JY. Bile acid signaling in metabolic disease and drug therapy[J]. Pharmacol Rev, 2014, 66(4): 948-983. DOI: 10.1124/pr.113.008201
[8]	SINAL CJ, TOHKIN M, MIYATA M, et al. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis[J]. Cell, 2000, 102(6): 731-744. DOI: 10.1016/S0092-8674(00)00062-3
[9]	WANG H, CHEN J, HOLLISTER K, et al. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR[J]. Mol Cell, 1999, 3(5): 543-553. DOI: 10.1016/S1097-2765(00)80348-2
[10]	YUAN L, BAMBHA K. Bile acid receptors and nonalcoholic fatty liver disease[J]. World J Hepatol, 2015, 7(28): 2811-2818. DOI: 10.4254/wjh.v7.i28.2811
[11]	MATSUBARA T, LI F, GONZALEZ FJ. FXR signaling in the enterohepatic system[J]. Mol Cell Endocrinol, 2013, 368(1-2): 17-29. DOI: 10.1016/j.mce.2012.05.004
[12]	HOLT JA, LUO G, BILLIN AN, et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis[J]. Genes Dev, 2003, 17(13): 1581-1591. DOI: 10.1101/gad.1083503
[13]	KOELFAT K, VISSCHERS R, HODIN C, et al. FXR agonism protects against liver injury in a rat model of intestinal failure-associated liver disease[J]. J Clin Transl Res, 2018, 3(3): 318-327. https://www.zhangqiaokeyan.com/academic-journal-cn_clinical-translational-research_thesis/0201277661820.html
[14]	TANG L. Practice in the study of intestinal microecology in China[J]. Chin J Gastroenterol Hepatol, 2019, 28(3): 241-244. (in Chinese) DOI: 10.3969/j.issn.1006-5709.2019.03.001 唐立. 中国肠道微生态学研究的实践[J]. 胃肠病学和肝病学杂志, 2019, 28(3): 241-244. DOI: 10.3969/j.issn.1006-5709.2019.03.001
[15]	NIE YF, HU J, YAN XH. Cross-talk between bile acids and intestinal microbiota in host metabolism and health[J]. J Zhejiang Univ Sci B, 2015, 16(6): 436-446. DOI: 10.1631/jzus.B1400327
[16]	VERBEKE L, FARRE R, VERBINNEN B, et al. The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats[J]. Am J Pathol, 2015, 185(2): 409-419. DOI: 10.1016/j.ajpath.2014.10.009
[17]	PAOLELLA G, MANDATO C, PIERRI L, et al. Gut-liver axis and probiotics: Their role in non-alcoholic fatty liver disease[J]. World J Gastroenterol, 2014, 20(42): 15518-15531. DOI: 10.3748/wjg.v20.i42.15518
[18]	ZHENG X, HUANG F, ZHAO A, et al. Bile acid is a significant host factor shaping the gut microbiome of diet-induced obese mice[J]. BMC Biol, 2017, 15(1): 120. DOI: 10.1186/s12915-017-0462-7
[19]	FRIEDMAN ES, LI Y, SHEN TD, et al. FXR-dependent modulation of the human small intestinal microbiome by the bile acid derivative obeticholic acid[J]. Gastroenterology, 2018, 155(6): 1741-1752. e5. DOI: 10.1053/j.gastro.2018.08.022
[20]	LI F, JIANG C, KRAUSZ KW, et al. Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity[J]. Nat Commun, 2013, 4: 2384. DOI: 10.1038/ncomms3384
[21]	ZHANG Y, LIMAYE PB, RENAUD HJ, et al. Effect of various antibiotics on modulation of intestinal microbiota and bile acid profile in mice[J]. Toxicol Appl Pharmacol, 2014, 277(2): 138-145. DOI: 10.1016/j.taap.2014.03.009
[22]	MISTRY RH, VERKADE HJ, TIETGE UJ. Reverse cholesterol transport is increased in germ-free mice-brief report[J]. Arterioscler Thromb Vasc Biol, 2017, 37(3): 419-422. DOI: 10.1161/ATVBAHA.116.308306
[23]	DEGIROLAMO C, RAINALDI S, BOVENGA F, et al. Microbiota modification with probiotics induces hepatic bile acid synthesis via downregulation of the Fxr-Fgf15 axis in mice[J]. Cell Rep, 2014, 7(1): 12-18. DOI: 10.1016/j.celrep.2014.02.032
[24]	YU YC, CHEN CW. Current status and research interests of the diagnosis and treatment of cholestatic liver disease[J]. J Clin Hepatol, 2019, 35(2): 241-246. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2019.02.001 于乐成, 陈成伟. 胆汁淤积性肝病的诊治现状及研究方向[J]. 临床肝胆病杂志, 2019, 35(2): 241-246. DOI: 10.3969/j.issn.1001-5256.2019.02.001
[25]	WANG XR, YAN BZ, YANG BS. The prognostic assessment of model for end-stage liver disease (MELD) and total bile acids in patients with subacute liver failure[J]. J Clin Hepatol, 2011, 27(6): 638-640. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2011.06.023 王晓韧, 颜炳柱, 杨宝山. 终末期肝病模型联合总胆汁酸对亚急性肝衰竭患者预后的评估[J]. 临床肝胆病杂志, 2011, 27(6): 638-640. DOI: 10.3969/j.issn.1001-5256.2011.06.023
[26]	MCMILLIN M, FRAMPTON G, QUINN M, et al. Bile acid signaling is involved in the neurological decline in a murine model of acute liver failure[J]. Am J Pathol, 2016, 186(2): 312-323. DOI: 10.1016/j.ajpath.2015.10.005
[27]	MODICA S, PETRUZZELLI M, BELLAFANTE E, et al. Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis[J]. Gastroenterology, 2012, 142(2): 355-365. e1-e4. DOI: 10.1053/j.gastro.2011.10.028
[28]	KONG B, ZHANG M, HUANG M, et al. FXR deficiency alters bile acid pool composition and exacerbates chronic alcohol induced liver injury[J]. Dig Liver Dis, 2019, 51(4): 570-576. DOI: 10.1016/j.dld.2018.12.026
[29]	LIAN F, WANG Y, XIAO Y, et al. Activated farnesoid X receptor attenuates apoptosis and liver injury in autoimmune hepatitis[J]. Mol Med Rep, 2015, 12(4): 5821-5827. DOI: 10.3892/mmr.2015.4159
[30]	ZHANG DG, ZHANG C, WANG JX, et al. Obeticholic acid protects against carbon tetrachloride-induced acute liver injury and inflammation[J]. Toxicol Appl Pharmacol, 2017, 314: 39-47. DOI: 10.1016/j.taap.2016.11.006
[31]	GAO FY, WANG XB. The role of intestinal endotoxemia in liver failure and its complications[J]. J Clin Hepatol, 2014, 30(8): 825-828. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2014.08.036 高方媛, 王宪波. 肠源性内毒素血症在肝衰竭发生发展中的作用[J]. 临床肝胆病杂志, 2014, 30(8): 825-828. DOI: 10.3969/j.issn.1001-5256.2014.08.036
[32]	BI MH, ZHANG SW, WANG BE, et al. Endotoxemia in rat hepatocyte mitochondria and its mechanism[J]. Chin J Appl Physiol, 2004, 20(1): 90-91, 97. (in Chinese) DOI: 10.3969/j.issn.1000-6834.2004.01.033 毕铭华, 张淑文, 王宝恩, 等. 内毒素血症对大鼠肝细胞线粒体的损伤及其机制[J]. 中国应用生理学杂志, 2004, 20(1): 90-91, 97. DOI: 10.3969/j.issn.1000-6834.2004.01.033
[33]	ZHANG YC, BI YZ, FANG X, et al. Protective effect of probiotics in rats with acute- on-chronic liver failure and related mechanism[J]. J Clin Hepatol, 2019, 35(7): 1570-1575. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2019.07.029 张永超, 毕研贞, 方萧, 等. 益生菌对慢加急性肝衰竭大鼠模型的保护作用及其机制[J]. 临床肝胆病杂志, 2019, 35(7): 1570-1575. DOI: 10.3969/j.issn.1001-5256.2019.07.029
[34]	ZHOU Y, DU S, CHEN B. The theory of an intestinal microecological imbalance[J]. J Pathog Biol, 2019, 14(7): 867-870. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-ZISC201907029.htm 周月, 杜珊, 陈斌. 肠道微生态失衡理论的研究现状[J]. 中国病原生物学杂志, 2019, 14(7): 867-870. https://www.cnki.com.cn/Article/CJFDTOTAL-ZISC201907029.htm
[35]	DELZENNE NM, KNUDSEN C, BEAUMONT M, et al. Contribution of the gut microbiota to the regulation of host metabolism and energy balance: A focus on the gut-liver axis[J]. Proc Nutr Soc, 2019, 78(3): 319-328. DOI: 10.1017/S0029665118002756
[36]	ANTONIADES CG, BERRY PA, WENDON JA, et al. The importance of immune dysfunction in determining outcome in acute liver failure[J]. J Hepatol, 2008, 49(5): 845-861. DOI: 10.1016/j.jhep.2008.08.009
[37]	JIANG LN, ZHAO JM. Clinicopathological basis of liver failure[J]. J Clin Hepatol, 2019, 35(9): 1916-1919. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2019.09.005 蒋丽娜, 赵景民. 肝衰竭的临床病理基础[J]. 临床肝胆病杂志, 2019, 35(9): 1916-1919. DOI: 10.3969/j.issn.1001-5256.2019.09.005
[38]	MICHALOPOULOS GK. Liver regeneration after partial hepatectomy: Critical analysis of mechanistic dilemmas[J]. Am J Pathol, 2010, 176(1): 2-13. DOI: 10.2353/ajpath.2010.090675
[39]	DU HP, CHEN W, KONG FD, et al. Effect of bile acid on expression of farnesoid X receptor, interleukin-6 and recovery of liver function after hepatectomy in rats with cirrhosis of liver[J/CD]. Chin J Injury Repair and Wound Healing (Electronic Edition), 2018, 13(6): 450-454. (in Chinese) 杜汉朋, 陈伟, 孔凡东, 等. 胆汁酸对肝硬化大鼠肝切除术后法尼酯X受体、白细胞介素-6的表达及肝功能恢复的影响[J/CD]. 中华损伤与修复杂志(电子版), 2018, 13(6): 450-454.
[40]	SUN SQ, QIU YD. Bile acid and farnesoid X receptor mediate liver regeneration[J/CD]. Chin J Exp Surg (Electronic Edition), 2017, 6(2): 147-149. (in Chinese) 孙士全, 仇毓东. 胆汁酸与法尼酯X受体介导肝再生[J/CD]. 中华肝脏外科手术学电子杂志, 2017, 6(2): 147-149.
[41]	DING L, YANG Y, QU Y, et al. Bile acid promotes liver regeneration via farnesoid X receptor signaling pathways in rats[J]. Mol Med Rep, 2015, 11(6): 4431-4437. DOI: 10.3892/mmr.2015.3270
[42]	ZHANG L, HUANG X, MENG Z, et al. Significance and mechanism of CYP7a1 gene regulation during the acute phase of liver regeneration[J]. Mol Endocrinol, 2009, 23(2): 137-145. DOI: 10.1210/me.2008-0198
[43]	LU YM, YUAN SG, LIANG KW, et al. Relationship between farnesoid X receptor and liver regeneration of obstructive jaundice rats following partial hepatectomy with different biliary drainages[J]. Chin J Exp Surg, 2014, 31(2): 304-307. (in Chinese) DOI: 10.3760/cma.j.issn.1001-9030.2014.02.028 鲁育民, 袁晟光, 梁科伟, 等. 法尼酯衍生物X受体与不同引流方式下梗阻性黄疸大鼠部分肝切除术后肝再生的关系[J]. 中华实验外科杂志, 2014, 31(2): 304-307. DOI: 10.3760/cma.j.issn.1001-9030.2014.02.028
[44]	CHEN WD, WANG YD, ZHANG L, et al. Farnesoid X receptor alleviates age-related proliferation defects in regenerating mouse livers by activating forkhead box m1b transcription[J]. Hepatology, 2010, 51(3): 953-962. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_PM19998409
[45]	KONG B, SUN R, HUANG M, et al. Fibroblast growth factor 15-dependent and bile acid-independent promotion of liver regeneration in mice[J]. Hepatology, 2018, 68(5): 1961-1976. DOI: 10.1002/hep.30041
[46]	LI J, GUO C, HE ZL, et al. Effect of fibroblast growth factor-15 on liver function and regeneration in rats with biliary obstruction by regulating bile acid metabolism[J]. J Hunan Normal Univ(Med Sci), 2019, 16(2): 3-7. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-HNYG201902003.htm 李佳, 郭超, 何自力, 等. FGF-15调节胆汁酸代谢对梗阻性黄疸大鼠肝功能及肝再生的影响[J]. 湖南师范大学学报(医学版), 2019, 16(2): 3-7. https://www.cnki.com.cn/Article/CJFDTOTAL-HNYG201902003.htm
[47]	XIE JF, FAN JY, YUAN SG. A study on exogenous bile acid for recovery of liver regeneration disorder caused by external biliary drain-age and its mechanism[J]. J Pract Med, 2018, 34(19): 3198-3202. (in Chinese) DOI: 10.3969/j.issn.1006-5725.2018.19.011 谢经丰, 范基元, 袁晟光. 外源性胆汁酸恢复胆道外引流导致的肝再生障碍及其机制[J]. 实用医学杂志, 2018, 34(19): 3198-3202. DOI: 10.3969/j.issn.1006-5725.2018.19.011
[48]	SUI CQ, MA YH, ZHAO Y, et al. Progress in the study of the protective mechanism and agonists of FXR in liver diseases[J]. Tianjin Pharmacy, 2019, 31(1): 49-54. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-TJYA201901018.htm 隋常琪, 马宇衡, 赵岩, 等. FXR在肝脏疾病中的作用及其激动剂的研究进展[J]. 天津药学, 2019, 31(1): 49-54. https://www.cnki.com.cn/Article/CJFDTOTAL-TJYA201901018.htm
[49]	BAO Q, YU L, CHEN D, et al. Variation in the gut microbial community is associated with the progression of liver regeneration[J]. Hepatol Res, 2020, 50(1): 121-136. DOI: 10.1111/hepr.13424
[50]	WU X, SUN R, CHEN Y, et al. Oral ampicillin inhibits liver regeneration by breaking hepatic innate immune tolerance normally maintained by gut commensal bacteria[J]. Hepatology, 2015, 62(1): 253-264. DOI: 10.1002/hep.27791
[51]	LIU HX, ROCHA CS, DANDEKAR S, et al. Functional analysis of the relationship between intestinal microbiota and the expression of hepatic genes and pathways during the course of liver regeneration[J]. J Hepatol, 2016, 64(3): 641-650. DOI: 10.1016/j.jhep.2015.09.022
[52]	CHEN YJ, XU CP, MI JJ. Intestinal endotoxemia induced dynamic changes of IL-1β in plasma and residual liver tissue after partial hepatectomy in rats[J]. Int J Dig Dis, 2011, 31(3): 172-176. (in Chinese) DOI: 10.3969/j.issn.1673-534X.2011.03.015 陈永静, 许翠萍, 米俊杰. 肝大部切除大鼠所致的IETM对血浆与肝组织IL-1β的影响[J]. 国际消化病杂志, 2011, 31(3): 172-176. DOI: 10.3969/j.issn.1673-534X.2011.03.015
[53]	REN QF, XU CP. Intestinal endotoxin-mediated liver injury affects the microenvironment of liver regeneration[J]. Chin Hepatol, 2018, 23(3): 263-266. (in Chinese) DOI: 10.3969/j.issn.1008-1704.2018.03.024 任勤芳, 许翠萍. 肠源性内毒素介导肝损伤影响肝再生微环境[J]. 肝脏, 2018, 23(3): 263-266. DOI: 10.3969/j.issn.1008-1704.2018.03.024
[54]	LUO L, REEDY AR, JONES RM. Detecting reactive oxygen species generation and stem cell proliferation in the drosophila intestine[J]. Methods Mol Biol, 2016, 1422: 103-113. DOI: 10.1007%2F978-1-4939-3603-8_10
[55]	WANG J, CEN P, CHEN J, et al. Role of mesenchymal stem cells, their derived factors, and extracellular vesicles in liver failure[J]. Stem Cell Res Ther, 2017, 8(1): 137. DOI: 10.1186/s13287-017-0576-4
[56]	LI WW, BAO CY, LI YM. Effect of bone marrow mesenchymal stem cell transplantation on acute liver failure and its effect on IL-10 level[J]. Chin J Immunol, 2020, 36(7): 774-779. (in Chinese) DOI: 10.3969/j.issn.1000-484X.2020.07.002 李文武, 鲍传裕, 李元明. 骨髓间充质干细胞移植在急性肝衰竭中的应用效果及对IL-10水平的影响研究[J]. 中国免疫学杂志, 2020, 36(7): 774-779. DOI: 10.3969/j.issn.1000-484X.2020.07.002
[57]	ZHANG RZ, WANG TS, LYU C, et al. The research progress of the mechanism of traditional Chinese medicine in the treatment of hepatic failure[J]. J Tradit Chin Med Univ Hunan, 2020, 40(2): 251-255. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-HNZX202002027.htm 张荣臻, 王挺帅, 吕超, 等. 中药治疗肝衰竭机制的研究进展[J]. 湖南中医药大学学报, 2020, 40(2): 251-255. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZX202002027.htm
[58]	WANG XB, ZHANG Q, GAO FY. Prediction of acute -on - chronic liver failure and integrated traditional Chinese and Western medicine therapy[J]. J Clin Hepatol, 2020, 36(1): 19-25. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2020.01.003 王宪波, 张群, 高方媛. 慢加急性肝衰竭的预后评估及中西医结合治疗[J]. 临床肝胆病杂志, 2020, 36(1): 19-25. DOI: 10.3969/j.issn.1001-5256.2020.01.003
[59]	LYU C, MAO DW, QIN Q, et al. Effect of Wenyang Huayu Tuihuang Decoction in the treatment of hepatitis B-related chronic and acute liver failure[J]. China Med Herald, 2019, 16(30): 142-146. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY201930031.htm 吕超, 毛德文, 覃倩, 等. 温阳化瘀退黄方治疗乙型肝炎相关慢加急性肝衰竭的效果[J]. 中国医药导报, 2019, 16(30): 142-146. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY201930031.htm

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (509) PDF downloads(39)

Mechanism of action of bile acid-farnesoid X receptor-intestinal microecological axis in the development of liver failure and liver regeneration

DOI: 10.3969/j.issn.1001-5256.2021.02.049

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Mechanism of action of bile acid-farnesoid X receptor-intestinal microecological axis in the development of liver failure and liver regeneration

DOI: 10.3969/j.issn.1001-5256.2021.02.049

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content